Diabetes Monitoring Opportunity to position the G1A Rapid Diabetes Monitoring Index Test as a scalable POC solution for clinics and OTC channels, capitalizing on the growing global diabetes management market and the need for monthly monitoring tools.

Small Company Advantage Target mid-market health systems and independent clinics that favor nimble, innovative vendors; emphasize fast deployment, personalized support, and flexible integration with existing systems to offset competitors with longer sales cycles.

Strategic Partnerships Leverage proximity to major biotech hubs near Irvine to pursue collaborations with universities, medical device accelerators, and contract manufacturers, unlocking co-development, testing, and distribution opportunities.

Digital Health Expansion Capitalize on the Am I Diabetic app to cross-sell the G1A test with digital tools, offering an integrated patient monitoring stack, data capture, and remote patient management that aligns with telehealth and OTC retail channels.

Funding Signals With existing revenue and moderate funding, approach venture capital and strategic investors for co-investment in scale-up, manufacturing partnerships, and international market entry to accelerate growth and distribution reach.